Fibroblast activation protein (FAP) is expressed as a pro-inflammatory agent from fibrous tissue in liver cirrhosis and in the tumor microenvironment. Cirrhosis is the last stage of any chronic liver disease, and the natural course of cirrhosis is the progression from the asymptomatic phase to the symptomatic decompensated phase with the development of ascites. Although various clinical features suggest cirrhosis in patients with chronic liver disease, non-invasive methods should follow the clinical approach before a definitive diagnosis. Herein, we present three cases of liver cirrhosis with fibroblast activation protein inhibitor (FAPI) uptake to demonstrate the usefulness of68Ga-FAPI-04 positron emission tomography/computed tomography (PET/CT) scan in cirrhosis.
CITATION STYLE
Tatar, G., Beyhan, E., Fenercioğlu, Ö. E., Sevindir, İ., Ergül, N., & Çermik, T. F. (2023). 68Ga-FAPI-04 PET/CT Findings in Patients with Liver Cirrhosis. Molecular Imaging and Radionuclide Therapy, 32(2), 146–149. https://doi.org/10.4274/mirt.galenos.2022.80774
Mendeley helps you to discover research relevant for your work.